Corbus Pharmaceuticals Stock Gains on ESMO Presentation Acceptance
Shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) climbed 2.4% on Tuesday after the company announced that an abstract featuring updated data from its key cancer drug trial has been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025.
The presentation will focus on CRB-701, a next-generation Nectin-4 targeting antibody-drug conjugate. The abstract will detail updated clinical findings from the ongoing Phase 1/2 study, which is testing the drug in patients with various solid tumors, including urothelial carcinoma. The poster is scheduled to be presented on October 19, 2025, at the congress in Berlin, Germany.
Corbus is currently conducting the dose optimization portion (Part B) of the three-part study. This phase is evaluating CRB-701 at two different dose levels in patients with head and neck squamous cell carcinoma, cervical cancer, and metastatic urothelial carcinoma. The company has already completed the initial dose escalation phase (Part A) of the trial.
Looking ahead, the clinical-stage oncology and obesity company expects to complete the dose optimization and establish a recommended dose for a future Phase 2 trial in the fourth quarter of 2025.
